Many Investors Still Treating Gilead: 4 Launches This Year Could Prove Them Wrong
Gilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Post-mistake savings require quick wins and steady progress: cut nonessential costs, automate savings, and reassess your priorities.
21,607 articlesGilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Gas prices swung in 2026 amid Middle East tensions, lifting refining margins. This article identifies the stocks pois...
Wildfire smoke blankets major U.S. cities, pushing air quality warnings higher and nudging investment flows toward cl...
Markets keep climbing amid strong earnings and AI-led investment. This article explains why this bull market crushing...
As Netflix stumbles, investors wonder if Disney down 2026 offers a rare contrarian opportunity. This article digs int...
The 13F filings show billionaire david tepper goes big on Alphabet, Micron, and Meta, while dialing back on Alibaba a...
Energy Transfer is redefining growth in the energy sector. This article breaks down how the company sustains a moment...
A new wave of AI infrastructure spending from Meta Platforms is shaping the outlook for Nvidia and the cloud ecosyste...
A reliable dividend is a powerful tool for building wealth. This high-yield pharma beast offers steady income, a robu...
A new market for tariff refunds is taking shape as courts clarify refund rights, drawing funds and individuals into a...
Concentra's Q4 2025 results shed light on its growth engine and profitability. This article breaks down the numbers, ...
A federal judge sent Nevada's cases against Kalshi and Polymarket back to state court, opening the door for temporary...